Literature DB >> 35312119

Determination of diagnostic threshold in harmonization and comparison of clinical utility for five major antiphospholipid antibody assays used in Japan.

Risa Kaneshige1,2, Yukari Motoki1,2, Mika Yoshida1,3, Kenji Oku1,4, Eriko Morishita1,5, Masahiro Ieko1,6, Kiyoshi Ichihara2, Junzo Nojima1,2.   

Abstract

BACKGROUND: Anticardiolipin antibodies (aCL) and anti-β2 -glycoprotein I antibodies (aβ2 GPI) are essential in diagnosing antiphospholipid syndrome (APS) according to the international APS guideline. Five commercial assays for aCL and aβ2 GPI are available in Japan, but their test results are quite discordant. For harmonization of diagnosing APS, upper reference limit (URL) and diagnostic accuracy of each assay were evaluated and compared by testing common sets of specimens across all assays.
METHODS: We evaluated two manual and three automated assays for aCL and aβ2 GPI of IgG- and IgM classes. 99%URL (the upper limit of reference interval: as per guideline) together with 97.5%URL were determined by testing sera from 198 to 400 well-defined healthy subjects. Both URLs were compared with the cutoff values, which were determined based on ROC analysis by testing 50 each of plasma specimens from patients with/without APS. Diagnostic accuracy was evaluated as area under curve (AUC) of the ROC curve.
RESULTS: A variable degree of discrepancy between URLs and the cutoff values was observed, which was partly attributable to between-year assay variability. 97.5%URLs were set lower and closer to the cutoff values than 99%URLs. For all assays, diagnostic accuracies of both aβ2 GPI-IgG and aCL-IgG were generally high (AUC: 0.84-0.93); whereas those for IgM-class assays were low (AUC: 0.57-0.67), implicating its utility is limited to rare IgG negative APS cases.
CONCLUSION: To ensure harmonized APS diagnosis, the diagnostic thresholds of the five assays were evaluated by common procedures. Contrary to the guideline, 97.5%URL is rather recommended for diagnosing APS, which showed a closer match to the cutoff value.
© 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.

Entities:  

Keywords:  anti-β2-glycoprotein I antibodies; anticardiolipin antibodies; antiphospholipid antibodies; diagnostic threshold; method comparison

Mesh:

Substances:

Year:  2022        PMID: 35312119      PMCID: PMC9102671          DOI: 10.1002/jcla.24340

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   3.124


  18 in total

1.  The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus.

Authors:  Junzo Nojima; Yoshinori Iwatani; Etsuji Suehisa; Hirohiko Kuratsune; Yuzuru Kanakura
Journal:  Haematologica       Date:  2006-04-19       Impact factor: 9.941

2.  β₂-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator.

Authors:  Katharina Gropp; Nadia Weber; Michael Reuter; Sven Micklisch; Isabell Kopka; Teresia Hallström; Christine Skerka
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  The Asian project for collaborative derivation of reference intervals: (1) strategy and major results of standardized analytes.

Authors:  Kiyoshi Ichihara; Ferruccio Ceriotti; Tran Huu Tam; Shigeo Sueyoshi; Priscilla M K Poon; Mee Ling Thong; Yasushi Higashiuesato; Xuejing Wang; Hiromi Kataoka; Akemi Matsubara; Shu-Chu Shiesh; Dewi Muliaty; Jeong-Ho Kim; Masakazu Watanabe; Christopher W K Lam; Lothar Siekmann; Joseph B Lopez; Mauro Panteghini
Journal:  Clin Chem Lab Med       Date:  2013-07       Impact factor: 3.694

5.  aCL/β2GPI and aPS/PT show synergic thrombogenic effects in suppressing anticoagulant activity of APC and stimulating tissue factor expression and TNF-α secretion by mononuclear cells.

Authors:  Risa Kaneshige; Junzo Nojima; Yukari Motoki; Hidehiro Tsuneoka
Journal:  Thromb Res       Date:  2019-07-12       Impact factor: 3.944

6.  Significance of fully automated tests for the diagnosis of antiphospholipid syndrome.

Authors:  Kenji Oku; Olga Amengual; Masaru Kato; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Naoya Sakamoto; Masahiro Ieko; Gary L Norman; Tatsuya Atsumi
Journal:  Thromb Res       Date:  2016-08-17       Impact factor: 3.944

7.  Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome.

Authors:  Cetin Agar; Gwendolyn M A van Os; Matthias Mörgelin; Richard R Sprenger; J Arnoud Marquart; Rolf T Urbanus; Ronald H W M Derksen; Joost C M Meijers; Philip G de Groot
Journal:  Blood       Date:  2010-05-12       Impact factor: 22.113

Review 8.  Antiphospholipid syndrome.

Authors:  Guillermo Ruiz-Irastorza; Mark Crowther; Ware Branch; Munther A Khamashta
Journal:  Lancet       Date:  2010-09-06       Impact factor: 79.321

9.  A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients.

Authors:  Junzo Nojima; Yukari Motoki; Natsumi Aoki; Hidehiro Tsuneoka; Kiyoshi Ichihara
Journal:  Thromb Res       Date:  2014-03-21       Impact factor: 3.944

Review 10.  Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.

Authors:  Silvia S Pierangeli; Pojen P Chen; Elena Raschi; Silvia Scurati; Claudia Grossi; Maria Orietta Borghi; Ivan Palomo; E Nigel Harris; Pier Luigi Meroni
Journal:  Semin Thromb Hemost       Date:  2008-04       Impact factor: 4.180

View more
  1 in total

1.  Determination of diagnostic threshold in harmonization and comparison of clinical utility for five major antiphospholipid antibody assays used in Japan.

Authors:  Risa Kaneshige; Yukari Motoki; Mika Yoshida; Kenji Oku; Eriko Morishita; Masahiro Ieko; Kiyoshi Ichihara; Junzo Nojima
Journal:  J Clin Lab Anal       Date:  2022-03-21       Impact factor: 3.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.